|
2.6 Etiologie - Environnement
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.2.3 Pharma - économie
|
|
|
Roche and Novartis face off in biosimilar drug battle [Reuters]
|
|
|
|
|
|
With
a copycat of Roche's blood cancer drug Rituxan pending European
approval, Novartis aims to muscle in on a share of sales that last year
hit 7 billion Swiss francs ($7.1 billion). But Roche is fighting back
with a new medicine, Gazyva, which it contends is better than Rituxan.
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
Six medicines win backing for EU approval [PharmaTimes]
|
|
|
|
|
|
Three
new generic medicines also won CHMP backing: Bortezomib Hospira
(bortezomib) and Bortezomib Sun (bortezomib) for the treatment of
multiple myeloma and mantle cell lymphoma; and Pemetrexed Fresenius Kabi
(pemetrexed) for the treatment of unresectable malignant pleural
mesothelioma and locally advanced or metastatic non-small cell lung
cancer.
|
|
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.6 Publications
|
|
|
|
6.9 Controverses
|
|
|
Cancer moonshot and slow-learners [The Mermaid's Tale]
|
|
|
|
|
|
In
this sense all the marketing rhetoric about 'precision' genomic
medicine is playing a game with the public, and the game is for
money--research money among other things. There's no cure for mortality
or the reality of aging.
|
|
|
|
|
|